Table 1.

Clinical profiles at baseline by 4 trajectory groups over the 55-month follow-up period

	High (n=177)	Increasing (n=136)	Decreasing (n=148)	Low (n=334)	Total (n=795)
Clinic site location, % **
East coast	25.4	33.1	36.5	46.7	37.7
West coast	74.6	66.9	63.5	53.3	62.3
Randomized conditions, % *
Buprenorphine	64.4	54.4	64.9	53.9	58.4
Methadone	35.6	45.6	35.1	46.1	41.6
Age at baseline, Mean(SD) **	38.9 (10.6)	38.2 (11.0)	36.8 (11.5)	36.6 (11.3)	37.4(11.2)
Female, %	32.2	35.3	31.1	35.9	34.1
Race/Ethnicity, % **
White	59.9	69.1	75.7	79.3	72.5
African American	10.2	13.2	7.4	7.8	9.2
Hispanic	20.9	11.0	10.1	6.6	11.3
Other	9.0	6.6	6.8	6.3	7.0
# Cigarettes smoked per day, %
0	10.2	9.6	9.4	12.6	10.9
<10	24.9	38.2	23.7	26.0	27.4
11–20	50.9	42.6	49.3	43.4	46.0
21–30	11.8	8.1	11.5	12.9	11.6
31+	2.2	1.5	6.0	5.1	4.0
Alcohol use, %	28.3	33.1	27.0	32.8	30.8
Cocaine positive, %	31.6	36.0	35.8	31.4	33.1
Amphetamine positive, %	10.2	10.3	6.1	5.1	7.3
Cannabinoids positive, %	20.9	25.0	19.6	20.7	21.3
Drug injection in past 30 days, % **	77.4	66.2	75.0	55.4	65.8
SF-36 Physical Component Summary, Mean (SD)	49.5 (8.8)	48.8 (9.2)	49.5 (9.2)	49.2 (9.4)	49.3 (9.2)
SF-36 Mental Component Summary, Mean (SD) **	41.9 (12.0)	39.0 (11.4)	39.8 (13.0)	37.9 (13.5)	39.3 (12.8)

^*p<0.05;

^**p<0.01